EntreMed raises $10.7M; Merck KGaA rules out big M&A deals;

 @FierceBiotech: Aastrom lands a new CEO in a game of musical biotech chairs. News | Follow @FierceBiotech

@JohnCFierce: I'd be willing to bet that Perlmutter has a couple of billion-dollar deals--like BioVex/Micromet--up his sleeves. Merck needs PhIII assets. | Follow @JohnCFierce

@RyanMFierce: I wonder whether Perlmutter will keep plugging away at CETP and other questionable Merck programs. | Follow @RyanMFierce

> EntreMed is raising $10.7 million from Kleiner Perkins Caufield Byers China Fund II L.P. and IDG-Accel China Growth Fund III L.P. Report

> Merck KGaA's CFO has ruled out any big acquisitions this year. Story

> The U.K.'s PolyTherics has received an undisclosed milestone payment from Celtic Pharma Holdings after reporting "further progress on their hematology alliance to produce longer-acting versions of blood factor proteins." Release

Pharma News

@FiercePharma: On 2nd thought: U.K. cost agency backs Novartis asthma drug Xolair. New discount, new analyses, NICE says. More | Follow @FiercePharma

@EricPFierce: Impax handed a 12-page Form 483 for a California plant by FDA. Plant must get OK before FDA will consider Impax NDA. Story | Follow @EricPFierce

> Israel should brace itself for Teva job cuts, analysts say. Report

> Sales reps, don your badges. We'll be watching you. More

> Glaxo chief loses half his incentive pay, cutting total to $5.86M. Story

Medical Device News

 @FierceMedDev: DBS helped some anorexia patients eat more. Item | Follow @FierceMedDev

 @MarkHFierce: Fierce 15 company Nevro just closed $48M in Series C financing. Yet ANOTHER robust device funding round. Release | Follow @MarkHFierce

 @DamianFierce: Illumina, SynapDx ally to develop autism diagnostic tools. Article | Follow @DamianFierce

> Renal denervation: Medtronic reaches for broader patient population. Article

> On second thought, Boston Scientific will unveil all Watchman data. News

> Stomach cancer breath Dx performs well in human tests. More

Pharma Manufacturing News

> Merck to close plant in Ireland. News

> Teva manufacturing cuts may have to involve home turf. More

> Ajinomoto buying biologics CMO Althea. Report

Vaccines News

> Sequester cuts set to hit vaccines. Report

> Study pins cancer vaccine failures on self-sabotaging adjuvant. Story

> GSK lawsuit shows risks of vaccine outsourcing. More

> Novartis encouraged by typhoid vaccine progress. Article

And Finally… Investigators say that even mild trauma can quickly kill brain tissue, raising the need for better therapies. Release


Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.